Valuation: Assembly Biosciences, Inc.

Market Cap 502M 436M 406M 373M 704M 47.89B 715M 4.78B 1.88B 23.84B 1.88B 1.84B 79.95B P/E 2026 *
-24.1x
P/E 2027 * -9.09x
Enterprise Value 502M 436M 406M 373M 704M 47.89B 715M 4.78B 1.88B 23.84B 1.88B 1.84B 79.95B EV / Sales 2026 *
11x
EV / Sales 2027 * 15.6x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day-2.88%
1 week-0.82%
Current month-7.79%
1 month-5.06%
3 months-7.42%
6 months-3.91%
Current year-25.49%
1 week 24.5
Extreme 24.5
26.56
1 month 24.5
Extreme 24.5
29.94
Current year 21.8
Extreme 21.795
34.68
1 year 16.9
Extreme 16.9
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 31/12/2022
Director of Finance/CFO - 04/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 03/06/2026
Director/Board Member 61 13/12/2017
Director/Board Member 68 05/08/2019
Date Insider Type Main position Quantity % Market Cap.
04/06/26 Free

Director

8,000 0.0514%
29/03/26 Free

Chief Technology Officer

26,000 0.1671%
08/08/25 BuyCompany 4,591,840 72.2409%
Change 5-day change 1-year change 3-year change Capi.($)
-3.03%-0.82%+41.37%+90.24% 502M
-1.40%+2.59%-1.71%+11.28% 49.37B
-1.11%+13.04%+26.54%+5.11% 39.14B
-1.60%-0.14%+407.00%+619.85% 40.85B
-1.97%-3.31%+4.64%+47.09% 35.81B
-1.74%+8.42%+8.85%+48.87% 30.5B
-2.28%-3.36% - - 16.55B
-0.40%-4.27%+34.76%+127.40% 16.14B
+0.43%+0.51%-1.53%-33.73% 12.77B
-0.64%+2.65%+1.25%+8.92% 13.71B
Average -1.31%+4.86%+57.91%+102.78% 25.54B
Weighted average by Cap. -1.29%+6.70%+77.88%+130.03%

Financials

2026 *2027 *
Net sales 45.47M 39.53M 36.79M 33.78M 63.79M 4.34B 64.78M 434M 170M 2.16B 171M 167M 7.25B 32.25M 28.03M 26.09M 23.96M 45.24M 3.08B 45.94M 308M 121M 1.53B 121M 118M 5.14B
Net income -20.46M -17.79M -16.56M -15.2M -28.71M -1.95B -29.15M -195M -76.6M -972M -76.85M -75.16M -3.26B -56.38M -49.01M -45.62M -41.88M -79.09M -5.38B -80.32M -538M -211M -2.68B -212M -207M -8.98B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
31/07/26 US$25.34 -2.76% 57,054
30/07/26 US$26.06 +3.78% 55,726
29/07/26 US$25.11 -1.80% 153,276
28/07/26 US$25.57 -1.31% 86,407
27/07/26 US$25.91 +1.41% 79,179
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
26.06USD
Average target price
50.00USD
Spread / Average Target
+91.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock